Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 200

Results For "EMA"

2395 News Found

Lupin launches Molnulup to treat Covid-19
News | January 07, 2022

Lupin launches Molnulup to treat Covid-19

The drug is priced at Rs 2000 for a course of 40 tablets


Jubiant Therapeutics gets USFDA clearance for JBI-802 to treat solid tumours
Biotech | January 07, 2022

Jubiant Therapeutics gets USFDA clearance for JBI-802 to treat solid tumours

JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6


AstraZeneca and Neurimmune to develop and commercialise NI006
Biotech | January 07, 2022

AstraZeneca and Neurimmune to develop and commercialise NI006

Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition


Aurobindo Pharma rolls out Molnaflu in India
News | January 06, 2022

Aurobindo Pharma rolls out Molnaflu in India

The brand is now available pan-India through their distribution partner


Margins under pressure; domestic market growth to slow down: Nirmal Bang
News | January 06, 2022

Margins under pressure; domestic market growth to slow down: Nirmal Bang

A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies


NATHEALTH Home Care Forum launches white paper on healthcare delivery
Healthcare | January 06, 2022

NATHEALTH Home Care Forum launches white paper on healthcare delivery

10 implementation focused initiatives recommended to accelerate policy reforms, standardization of home care delivery services, and improve accessibility and affordability of care in tier II and tier III geographies


Biogen exercises option with Ionis for spinal muscular atrophy
Biotech | January 05, 2022

Biogen exercises option with Ionis for spinal muscular atrophy

Biogen paid Ionis a US $ 60 million one-time upfront payment


Amyris and ImmunityBio JV for next gen Covid-19 RNA vaccine
Biotech | January 04, 2022

Amyris and ImmunityBio JV for next gen Covid-19 RNA vaccine

Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible


Kyverna Therapeutics announces licence agreement with NIH
Biotech | January 04, 2022

Kyverna Therapeutics announces licence agreement with NIH

This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel


Domestic and emerging markets will drive pharma growth: ICRA
News | January 04, 2022

Domestic and emerging markets will drive pharma growth: ICRA

Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters